HomeAbout NAIManufacturingNewsInvestor RelationsContact UsFAQFAQ
   About Us
   Executive Team
   Board of Directors
   Bus. Development
   Global Operations
   North America
   Europe & Asia
   Financial Data
   Annual Report
   Corp. Governance
   TGA Certification
   GMP Standards
   News & Blog
   CEO's Blog
   Industry Links

Natural Alternatives International, Inc. Announces Fiscal 2013 Results

SAN MARCOS, Calif., Sept. 19, 2013 -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $1.6 million, or $0.23 per diluted share, on net sales of $62.8 million for the fiscal year ended June 30, 2013.

Fiscal 2013 net sales from contract manufacturing activities decreased $6.6 million as compared to the prior fiscal year due primarily to lower volumes of existing products in existing markets, lower average sales prices for a portion of our higher volume products and lower average EUR exchange rates. Royalty and licensing income related to license agreements for the use of our CarnoSyn® beta-alanine related patents and trademarks increased 2% to $4.7 million during fiscal 2013 as compared to $4.6 million for fiscal 2012, and raw material sales of beta-alanine totaled $103,000 during fiscal 2013 as compared to $3.4 million for fiscal 2012.

During the second and third quarters of fiscal 2012, NAI purchased approximately $3.2 million of beta-alanine raw material to help ensure sufficient inventory to meet anticipated future customer demand. The majority of this raw material was sold or consumed during the third and fourth quarters of fiscal 2012. Due to the improvement in the worldwide supply of beta-alanine during late fiscal 2012, NAI discontinued its purchase and sale of beta-alanine raw materials during fiscal 2013. Net sales from our branded products declined $238,000 to $1.3 million during fiscal 2013 as compared to the prior fiscal year.

The fiscal 2013 net sales decreases, coupled with higher per unit manufacturing costs associated with lower production levels, contributed to a $4.0 million decrease in income from operations during fiscal 2013 as compared to the prior fiscal year.
Net income for fiscal 2013 was $1.6 million, or $0.23 per diluted share, as compared to net income of $4.2 million for fiscal 2012, or $0.59 per diluted share.

Net sales for the fourth quarter ended June 30, 2013 decreased to $16.8 million as compared to $20.9 million for the prior year period. The decrease in net sales during the current quarter was primarily related to a $3.0 million of reduction in beta-alanine raw material sales and decreased contract manufacturing sales from existing customers, which was partially offset by a $708,000 increase in royalty and licensing income. Net income in the fourth quarter of fiscal 2013 was $593,000, or $0.09 per diluted share, as compared to net income of $777,000, or $0.11 per diluted share, in the fourth quarter of fiscal 2012. The decrease in net income on a quarter over quarter basis was attributable primarily to lower contract manufacturing sales and beta-alanine raw material sales.

As of June 30, 2013, NAI had cash and cash equivalents of $16.7 million and working capital of $29.4 million compared to $14.5 million and $27.7 million, respectively, as of June 30, 2012. As of June 30, 2013, we had no debt outstanding and $5.5 million available under our working capital lines of credit.

Mark A. LeDoux, Chairman and Chief Executive Officer, stated, "During fiscal 2013 NAI experienced variable conditions in business activities that included customer driven inventory reductions, product pricing pressures and delayed new product launches. Even in the face of these headwinds, and our continued significant investment in prosecuting our growing patent estate, the fourth quarter demonstrated increases in patent and trademark royalty and licensing income through expanding acceptance of the usage of CarnoSyn® beta-alanine. While contract manufacturing sales were lower for a variety of reasons in the last fiscal year, we believe we remain poised to experience meaningful growth in both our top line sales and operating income for the entirety of fiscal 2014 primarily as a result of expanded demand from various existing and new customer relationships."

NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our future financial and operating results, including the amount of our future revenue and profits and our future financial condition, our ability to maintain our patents, generate revenues from the commercialization of our patents and trademarks, secure compliance with our intellectual property rights, and develop, maintain or increase sales to new and existing customers, as well as the availability of beta-alanine, future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.
CONTACT – Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or